Study wrapper · #1141
Efficacy and Hypoglycaemia Outcomes With Once-Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1-3 Trials.
Ji L, Andersen JD, Benamar M, et al. Diabetes, obesity & metabolism. 2026.
DOI: 10.1111/dom.70895PubMed: 42557064
Editor's note
This is a Novo Nordisk-sponsored post hoc slice of the COMBINE trials, asking whether the icodec-semaglutide combination performs consistently in patients with organ impairment — a practical question, since kidney and liver disease are common in type 2 diabetes. The answer is broadly yes, with a few scattered subgroup interactions that do not form a clear pattern. Incremental rather than headline material, but relevant context for semaglutide's expanding combination-therapy footprint.
Plain-language abstract
A follow-up analysis of three trials of IcoSema — a once-weekly combination of insulin icodec and semaglutide — found its blood-sugar and hypoglycemia results held up about equally well in people with reduced kidney or liver function.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026